Innovative Therapies Redefine Treatment Goals in Multiple Sclerosis

The treatment of multiple sclerosis (MS) is becoming more complex, especially with the expanding number of available therapies for relapsing forms of MS. Greater understanding of the degenerative aspects of MS pathogenesis is redefining treatment goals and creating new treatment strategies. The exis...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Ines Lazibat [verfasserIn] Radenka Kuzmanić Šamija [verfasserIn] Krešimir Rotim [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2016

Schlagwörter:	Multiple sclerosis – therapy Multiple sclerosis, relapsing-remitting – drug therapy Immunosuppressive agents – therapeutic use Treatment outcome

Übergeordnetes Werk:	In: Acta Clinica Croatica - Sestre Milosrdnice University hospital, Institute of Clinical Medical Research, 2018, 55.(2016), 1., Seite 125-133
Übergeordnetes Werk:	volume:55. ; year:2016 ; number:1. ; pages:125-133

Links:	Link aufrufen Link aufrufen Journal toc Journal toc

Katalog-ID:	DOAJ005455693

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ005455693
003	DE-627
005	20230503024918.0
007	cr uuu---uuuuu
008	230225s2016 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)DOAJ005455693
035			\|a (DE-599)DOAJ3710cbb015394cb19f0e902a17a0301e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
100	0		\|a Ines Lazibat \|e verfasserin \|4 aut
245	1	0	\|a Innovative Therapies Redefine Treatment Goals in Multiple Sclerosis
264		1	\|c 2016
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a The treatment of multiple sclerosis (MS) is becoming more complex, especially with the expanding number of available therapies for relapsing forms of MS. Greater understanding of the degenerative aspects of MS pathogenesis is redefining treatment goals and creating new treatment strategies. The existing immunomodulation drugs (disease-modifying therapies, DMTs) used in MS treatment have shown only partial benefits in controlling disease progression, primarily by reducing the inflammation component. However, new therapies for MS have been shown to be effective in delaying disease progression by protecting against brain atrophy, which is considered the most important preindicator of future patient disability. The favorable effect on reducing brain atrophy suggests the potential neuroprotective or even neuroregenerative effects of new treatments, marking progress in the treatment of MS.
650		4	\|a Multiple sclerosis – therapy
650		4	\|a Multiple sclerosis, relapsing-remitting – drug therapy
650		4	\|a Immunosuppressive agents – therapeutic use
650		4	\|a Treatment outcome
653		0	\|a Medicine
653		0	\|a R
700	0		\|a Radenka Kuzmanić Šamija \|e verfasserin \|4 aut
700	0		\|a Krešimir Rotim \|e verfasserin \|4 aut
773	0	8	\|i In \|t Acta Clinica Croatica \|d Sestre Milosrdnice University hospital, Institute of Clinical Medical Research, 2018 \|g 55.(2016), 1., Seite 125-133 \|w (DE-627)343513757 \|w (DE-600)2073072-X \|x 13339451 \|7 nnns
773	1	8	\|g volume:55. \|g year:2016 \|g number:1. \|g pages:125-133
856	4	0	\|u https://doaj.org/article/3710cbb015394cb19f0e902a17a0301e \|z kostenfrei
856	4	0	\|u http://hrcak.srce.hr/file/237771 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/0353-9466 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1333-9451 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 55. \|j 2016 \|e 1. \|h 125-133

Indexfelder

author_variant	i l il r k š rkš k r kr
matchkey_str	article:13339451:2016----::noaiehrperdfntetetolim
hierarchy_sort_str	2016
publishDate	2016
allfields	(DE-627)DOAJ005455693 (DE-599)DOAJ3710cbb015394cb19f0e902a17a0301e DE-627 ger DE-627 rakwb eng Ines Lazibat verfasserin aut Innovative Therapies Redefine Treatment Goals in Multiple Sclerosis 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The treatment of multiple sclerosis (MS) is becoming more complex, especially with the expanding number of available therapies for relapsing forms of MS. Greater understanding of the degenerative aspects of MS pathogenesis is redefining treatment goals and creating new treatment strategies. The existing immunomodulation drugs (disease-modifying therapies, DMTs) used in MS treatment have shown only partial benefits in controlling disease progression, primarily by reducing the inflammation component. However, new therapies for MS have been shown to be effective in delaying disease progression by protecting against brain atrophy, which is considered the most important preindicator of future patient disability. The favorable effect on reducing brain atrophy suggests the potential neuroprotective or even neuroregenerative effects of new treatments, marking progress in the treatment of MS. Multiple sclerosis – therapy Multiple sclerosis, relapsing-remitting – drug therapy Immunosuppressive agents – therapeutic use Treatment outcome Medicine R Radenka Kuzmanić Šamija verfasserin aut Krešimir Rotim verfasserin aut In Acta Clinica Croatica Sestre Milosrdnice University hospital, Institute of Clinical Medical Research, 2018 55.(2016), 1., Seite 125-133 (DE-627)343513757 (DE-600)2073072-X 13339451 nnns volume:55. year:2016 number:1. pages:125-133 https://doaj.org/article/3710cbb015394cb19f0e902a17a0301e kostenfrei http://hrcak.srce.hr/file/237771 kostenfrei https://doaj.org/toc/0353-9466 Journal toc kostenfrei https://doaj.org/toc/1333-9451 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 55. 2016 1. 125-133
spelling	(DE-627)DOAJ005455693 (DE-599)DOAJ3710cbb015394cb19f0e902a17a0301e DE-627 ger DE-627 rakwb eng Ines Lazibat verfasserin aut Innovative Therapies Redefine Treatment Goals in Multiple Sclerosis 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The treatment of multiple sclerosis (MS) is becoming more complex, especially with the expanding number of available therapies for relapsing forms of MS. Greater understanding of the degenerative aspects of MS pathogenesis is redefining treatment goals and creating new treatment strategies. The existing immunomodulation drugs (disease-modifying therapies, DMTs) used in MS treatment have shown only partial benefits in controlling disease progression, primarily by reducing the inflammation component. However, new therapies for MS have been shown to be effective in delaying disease progression by protecting against brain atrophy, which is considered the most important preindicator of future patient disability. The favorable effect on reducing brain atrophy suggests the potential neuroprotective or even neuroregenerative effects of new treatments, marking progress in the treatment of MS. Multiple sclerosis – therapy Multiple sclerosis, relapsing-remitting – drug therapy Immunosuppressive agents – therapeutic use Treatment outcome Medicine R Radenka Kuzmanić Šamija verfasserin aut Krešimir Rotim verfasserin aut In Acta Clinica Croatica Sestre Milosrdnice University hospital, Institute of Clinical Medical Research, 2018 55.(2016), 1., Seite 125-133 (DE-627)343513757 (DE-600)2073072-X 13339451 nnns volume:55. year:2016 number:1. pages:125-133 https://doaj.org/article/3710cbb015394cb19f0e902a17a0301e kostenfrei http://hrcak.srce.hr/file/237771 kostenfrei https://doaj.org/toc/0353-9466 Journal toc kostenfrei https://doaj.org/toc/1333-9451 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 55. 2016 1. 125-133
allfields_unstemmed	(DE-627)DOAJ005455693 (DE-599)DOAJ3710cbb015394cb19f0e902a17a0301e DE-627 ger DE-627 rakwb eng Ines Lazibat verfasserin aut Innovative Therapies Redefine Treatment Goals in Multiple Sclerosis 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The treatment of multiple sclerosis (MS) is becoming more complex, especially with the expanding number of available therapies for relapsing forms of MS. Greater understanding of the degenerative aspects of MS pathogenesis is redefining treatment goals and creating new treatment strategies. The existing immunomodulation drugs (disease-modifying therapies, DMTs) used in MS treatment have shown only partial benefits in controlling disease progression, primarily by reducing the inflammation component. However, new therapies for MS have been shown to be effective in delaying disease progression by protecting against brain atrophy, which is considered the most important preindicator of future patient disability. The favorable effect on reducing brain atrophy suggests the potential neuroprotective or even neuroregenerative effects of new treatments, marking progress in the treatment of MS. Multiple sclerosis – therapy Multiple sclerosis, relapsing-remitting – drug therapy Immunosuppressive agents – therapeutic use Treatment outcome Medicine R Radenka Kuzmanić Šamija verfasserin aut Krešimir Rotim verfasserin aut In Acta Clinica Croatica Sestre Milosrdnice University hospital, Institute of Clinical Medical Research, 2018 55.(2016), 1., Seite 125-133 (DE-627)343513757 (DE-600)2073072-X 13339451 nnns volume:55. year:2016 number:1. pages:125-133 https://doaj.org/article/3710cbb015394cb19f0e902a17a0301e kostenfrei http://hrcak.srce.hr/file/237771 kostenfrei https://doaj.org/toc/0353-9466 Journal toc kostenfrei https://doaj.org/toc/1333-9451 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 55. 2016 1. 125-133
allfieldsGer	(DE-627)DOAJ005455693 (DE-599)DOAJ3710cbb015394cb19f0e902a17a0301e DE-627 ger DE-627 rakwb eng Ines Lazibat verfasserin aut Innovative Therapies Redefine Treatment Goals in Multiple Sclerosis 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The treatment of multiple sclerosis (MS) is becoming more complex, especially with the expanding number of available therapies for relapsing forms of MS. Greater understanding of the degenerative aspects of MS pathogenesis is redefining treatment goals and creating new treatment strategies. The existing immunomodulation drugs (disease-modifying therapies, DMTs) used in MS treatment have shown only partial benefits in controlling disease progression, primarily by reducing the inflammation component. However, new therapies for MS have been shown to be effective in delaying disease progression by protecting against brain atrophy, which is considered the most important preindicator of future patient disability. The favorable effect on reducing brain atrophy suggests the potential neuroprotective or even neuroregenerative effects of new treatments, marking progress in the treatment of MS. Multiple sclerosis – therapy Multiple sclerosis, relapsing-remitting – drug therapy Immunosuppressive agents – therapeutic use Treatment outcome Medicine R Radenka Kuzmanić Šamija verfasserin aut Krešimir Rotim verfasserin aut In Acta Clinica Croatica Sestre Milosrdnice University hospital, Institute of Clinical Medical Research, 2018 55.(2016), 1., Seite 125-133 (DE-627)343513757 (DE-600)2073072-X 13339451 nnns volume:55. year:2016 number:1. pages:125-133 https://doaj.org/article/3710cbb015394cb19f0e902a17a0301e kostenfrei http://hrcak.srce.hr/file/237771 kostenfrei https://doaj.org/toc/0353-9466 Journal toc kostenfrei https://doaj.org/toc/1333-9451 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 55. 2016 1. 125-133
allfieldsSound	(DE-627)DOAJ005455693 (DE-599)DOAJ3710cbb015394cb19f0e902a17a0301e DE-627 ger DE-627 rakwb eng Ines Lazibat verfasserin aut Innovative Therapies Redefine Treatment Goals in Multiple Sclerosis 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The treatment of multiple sclerosis (MS) is becoming more complex, especially with the expanding number of available therapies for relapsing forms of MS. Greater understanding of the degenerative aspects of MS pathogenesis is redefining treatment goals and creating new treatment strategies. The existing immunomodulation drugs (disease-modifying therapies, DMTs) used in MS treatment have shown only partial benefits in controlling disease progression, primarily by reducing the inflammation component. However, new therapies for MS have been shown to be effective in delaying disease progression by protecting against brain atrophy, which is considered the most important preindicator of future patient disability. The favorable effect on reducing brain atrophy suggests the potential neuroprotective or even neuroregenerative effects of new treatments, marking progress in the treatment of MS. Multiple sclerosis – therapy Multiple sclerosis, relapsing-remitting – drug therapy Immunosuppressive agents – therapeutic use Treatment outcome Medicine R Radenka Kuzmanić Šamija verfasserin aut Krešimir Rotim verfasserin aut In Acta Clinica Croatica Sestre Milosrdnice University hospital, Institute of Clinical Medical Research, 2018 55.(2016), 1., Seite 125-133 (DE-627)343513757 (DE-600)2073072-X 13339451 nnns volume:55. year:2016 number:1. pages:125-133 https://doaj.org/article/3710cbb015394cb19f0e902a17a0301e kostenfrei http://hrcak.srce.hr/file/237771 kostenfrei https://doaj.org/toc/0353-9466 Journal toc kostenfrei https://doaj.org/toc/1333-9451 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 55. 2016 1. 125-133
language	English
source	In Acta Clinica Croatica 55.(2016), 1., Seite 125-133 volume:55. year:2016 number:1. pages:125-133
sourceStr	In Acta Clinica Croatica 55.(2016), 1., Seite 125-133 volume:55. year:2016 number:1. pages:125-133
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Multiple sclerosis – therapy Multiple sclerosis, relapsing-remitting – drug therapy Immunosuppressive agents – therapeutic use Treatment outcome Medicine R
isfreeaccess_bool	true
container_title	Acta Clinica Croatica
authorswithroles_txt_mv	Ines Lazibat @@aut@@ Radenka Kuzmanić Šamija @@aut@@ Krešimir Rotim @@aut@@
publishDateDaySort_date	2016-01-01T00:00:00Z
hierarchy_top_id	343513757
id	DOAJ005455693
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ005455693</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230503024918.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2016 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ005455693</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ3710cbb015394cb19f0e902a17a0301e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Ines Lazibat</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Innovative Therapies Redefine Treatment Goals in Multiple Sclerosis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The treatment of multiple sclerosis (MS) is becoming more complex, especially with the expanding number of available therapies for relapsing forms of MS. Greater understanding of the degenerative aspects of MS pathogenesis is redefining treatment goals and creating new treatment strategies. The existing immunomodulation drugs (disease-modifying therapies, DMTs) used in MS treatment have shown only partial benefits in controlling disease progression, primarily by reducing the inflammation component. However, new therapies for MS have been shown to be effective in delaying disease progression by protecting against brain atrophy, which is considered the most important preindicator of future patient disability. The favorable effect on reducing brain atrophy suggests the potential neuroprotective or even neuroregenerative effects of new treatments, marking progress in the treatment of MS.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Multiple sclerosis – therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Multiple sclerosis, relapsing-remitting – drug therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunosuppressive agents – therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Treatment outcome</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Radenka Kuzmanić Šamija</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Krešimir Rotim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Acta Clinica Croatica</subfield><subfield code="d">Sestre Milosrdnice University hospital, Institute of Clinical Medical Research, 2018</subfield><subfield code="g">55.(2016), 1., Seite 125-133</subfield><subfield code="w">(DE-627)343513757</subfield><subfield code="w">(DE-600)2073072-X</subfield><subfield code="x">13339451</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:55.</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:1.</subfield><subfield code="g">pages:125-133</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/3710cbb015394cb19f0e902a17a0301e</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://hrcak.srce.hr/file/237771</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0353-9466</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1333-9451</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">55.</subfield><subfield code="j">2016</subfield><subfield code="e">1.</subfield><subfield code="h">125-133</subfield></datafield></record></collection>
author	Ines Lazibat
spellingShingle	Ines Lazibat misc Multiple sclerosis – therapy misc Multiple sclerosis, relapsing-remitting – drug therapy misc Immunosuppressive agents – therapeutic use misc Treatment outcome misc Medicine misc R Innovative Therapies Redefine Treatment Goals in Multiple Sclerosis
authorStr	Ines Lazibat
ppnlink_with_tag_str_mv	@@773@@(DE-627)343513757
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut
collection	DOAJ
remote_str	true
illustrated	Not Illustrated
issn	13339451
topic_title	Innovative Therapies Redefine Treatment Goals in Multiple Sclerosis Multiple sclerosis – therapy Multiple sclerosis, relapsing-remitting – drug therapy Immunosuppressive agents – therapeutic use Treatment outcome
topic	misc Multiple sclerosis – therapy misc Multiple sclerosis, relapsing-remitting – drug therapy misc Immunosuppressive agents – therapeutic use misc Treatment outcome misc Medicine misc R
topic_unstemmed	misc Multiple sclerosis – therapy misc Multiple sclerosis, relapsing-remitting – drug therapy misc Immunosuppressive agents – therapeutic use misc Treatment outcome misc Medicine misc R
topic_browse	misc Multiple sclerosis – therapy misc Multiple sclerosis, relapsing-remitting – drug therapy misc Immunosuppressive agents – therapeutic use misc Treatment outcome misc Medicine misc R
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Acta Clinica Croatica
hierarchy_parent_id	343513757
hierarchy_top_title	Acta Clinica Croatica
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)343513757 (DE-600)2073072-X
title	Innovative Therapies Redefine Treatment Goals in Multiple Sclerosis
ctrlnum	(DE-627)DOAJ005455693 (DE-599)DOAJ3710cbb015394cb19f0e902a17a0301e
title_full	Innovative Therapies Redefine Treatment Goals in Multiple Sclerosis
author_sort	Ines Lazibat
journal	Acta Clinica Croatica
journalStr	Acta Clinica Croatica
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2016
contenttype_str_mv	txt
container_start_page	125
author_browse	Ines Lazibat Radenka Kuzmanić Šamija Krešimir Rotim
container_volume	55.
format_se	Elektronische Aufsätze
author-letter	Ines Lazibat
author2-role	verfasserin
title_sort	innovative therapies redefine treatment goals in multiple sclerosis
title_auth	Innovative Therapies Redefine Treatment Goals in Multiple Sclerosis
abstract	The treatment of multiple sclerosis (MS) is becoming more complex, especially with the expanding number of available therapies for relapsing forms of MS. Greater understanding of the degenerative aspects of MS pathogenesis is redefining treatment goals and creating new treatment strategies. The existing immunomodulation drugs (disease-modifying therapies, DMTs) used in MS treatment have shown only partial benefits in controlling disease progression, primarily by reducing the inflammation component. However, new therapies for MS have been shown to be effective in delaying disease progression by protecting against brain atrophy, which is considered the most important preindicator of future patient disability. The favorable effect on reducing brain atrophy suggests the potential neuroprotective or even neuroregenerative effects of new treatments, marking progress in the treatment of MS.
abstractGer	The treatment of multiple sclerosis (MS) is becoming more complex, especially with the expanding number of available therapies for relapsing forms of MS. Greater understanding of the degenerative aspects of MS pathogenesis is redefining treatment goals and creating new treatment strategies. The existing immunomodulation drugs (disease-modifying therapies, DMTs) used in MS treatment have shown only partial benefits in controlling disease progression, primarily by reducing the inflammation component. However, new therapies for MS have been shown to be effective in delaying disease progression by protecting against brain atrophy, which is considered the most important preindicator of future patient disability. The favorable effect on reducing brain atrophy suggests the potential neuroprotective or even neuroregenerative effects of new treatments, marking progress in the treatment of MS.
abstract_unstemmed	The treatment of multiple sclerosis (MS) is becoming more complex, especially with the expanding number of available therapies for relapsing forms of MS. Greater understanding of the degenerative aspects of MS pathogenesis is redefining treatment goals and creating new treatment strategies. The existing immunomodulation drugs (disease-modifying therapies, DMTs) used in MS treatment have shown only partial benefits in controlling disease progression, primarily by reducing the inflammation component. However, new therapies for MS have been shown to be effective in delaying disease progression by protecting against brain atrophy, which is considered the most important preindicator of future patient disability. The favorable effect on reducing brain atrophy suggests the potential neuroprotective or even neuroregenerative effects of new treatments, marking progress in the treatment of MS.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	1.
title_short	Innovative Therapies Redefine Treatment Goals in Multiple Sclerosis
url	https://doaj.org/article/3710cbb015394cb19f0e902a17a0301e http://hrcak.srce.hr/file/237771 https://doaj.org/toc/0353-9466 https://doaj.org/toc/1333-9451
remote_bool	true
author2	Radenka Kuzmanić Šamija Krešimir Rotim
author2Str	Radenka Kuzmanić Šamija Krešimir Rotim
ppnlink	343513757
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
up_date	2024-07-03T15:06:30.894Z
_version_	1803570843111915521
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ005455693</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230503024918.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2016 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ005455693</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ3710cbb015394cb19f0e902a17a0301e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Ines Lazibat</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Innovative Therapies Redefine Treatment Goals in Multiple Sclerosis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The treatment of multiple sclerosis (MS) is becoming more complex, especially with the expanding number of available therapies for relapsing forms of MS. Greater understanding of the degenerative aspects of MS pathogenesis is redefining treatment goals and creating new treatment strategies. The existing immunomodulation drugs (disease-modifying therapies, DMTs) used in MS treatment have shown only partial benefits in controlling disease progression, primarily by reducing the inflammation component. However, new therapies for MS have been shown to be effective in delaying disease progression by protecting against brain atrophy, which is considered the most important preindicator of future patient disability. The favorable effect on reducing brain atrophy suggests the potential neuroprotective or even neuroregenerative effects of new treatments, marking progress in the treatment of MS.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Multiple sclerosis – therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Multiple sclerosis, relapsing-remitting – drug therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunosuppressive agents – therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Treatment outcome</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Radenka Kuzmanić Šamija</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Krešimir Rotim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Acta Clinica Croatica</subfield><subfield code="d">Sestre Milosrdnice University hospital, Institute of Clinical Medical Research, 2018</subfield><subfield code="g">55.(2016), 1., Seite 125-133</subfield><subfield code="w">(DE-627)343513757</subfield><subfield code="w">(DE-600)2073072-X</subfield><subfield code="x">13339451</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:55.</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:1.</subfield><subfield code="g">pages:125-133</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/3710cbb015394cb19f0e902a17a0301e</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://hrcak.srce.hr/file/237771</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0353-9466</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1333-9451</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">55.</subfield><subfield code="j">2016</subfield><subfield code="e">1.</subfield><subfield code="h">125-133</subfield></datafield></record></collection>
score	7.4031916

Nicht das Richtige dabei?

Schreiben Sie uns!

Innovative Therapies Redefine Treatment Goals in Multiple Sclerosis

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?